Esperion Therapeutics, Inc.

1.19 USD
-0.05 (-3.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Esperion Therapeutics, Inc. stock is up 42.77% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT. 67% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
04 Oct 19:47 21 Jun, 2024 5.00 PUT 1672 1687

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.

  • JP Morgan
    Mon Nov 20, 08:25
  • HC Wainwright & Co.
    Mon Nov 13, 11:17
  • Needham
    Tue Nov 7, 15:28